Showing 1 - 10 of 708
We study the effect of price caps on the provision of costly effort by pharmaceutical firms using variation in drug discounts generated by a price regulation program that allows eligible hospitals to purchase outpatient drugs at steep discounts. These discounts directly affect drug...
Persistent link: https://www.econbiz.de/10014512103
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing, but net prices are...
Persistent link: https://www.econbiz.de/10012482027
A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health...
Persistent link: https://www.econbiz.de/10012463320
We analyze some of the perverse incentives that may arise under the current Medicare prescription drug benefit design. In particular, risk adjustment for a stand-alone prescription drug benefit creates perverse incentives for prescription drug plans' coverage decisions and/or pharmaceutical...
Persistent link: https://www.econbiz.de/10012466663
Selective contracting is an increasingly popular tool for reducing health care costs, but these savings must be weighed against consumer surplus losses from restricted access. In both public and private prescription drug insurance plans, issuers utilize preferred pharmacy networks to reduce drug...
Persistent link: https://www.econbiz.de/10012452859
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …
Persistent link: https://www.econbiz.de/10012470978
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic …
Persistent link: https://www.econbiz.de/10012471776
After receiving FDA approval, a generic drug manufacturer can launch "at risk" before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides...
Persistent link: https://www.econbiz.de/10012616579
The United States spends twice as much per person on pharmaceuticals as European countries, in large part because … reference countries. We estimate a structural model of demand and supply for pharmaceuticals in the US and reference countries …
Persistent link: https://www.econbiz.de/10013210081
Despite their importance to the supply of prescription drugs, there has been limited research on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug manufacturers. This paper provides an overview of the current state of research on this topic, motivates why...
Persistent link: https://www.econbiz.de/10013191054